Booking Holdings Inc. Stock Rises Monday, Outperforms Market

CNS Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

CNSP CNS Pharmaceuticals Inc

SMTC Semtech Corp

EU enCore Energy Corp

CJET Chijet Motor Co Inc

LAKE Lakeland Industries Inc

JWEL Jowell Global Ltd

SMAR Smartsheet Inc

FOXA Fox Corp

SCVFF Scotch Creek Ventures Inc

VEDU Visionary Education Technology Holdings Group Inc

Health Care : Pharmaceuticals | Small Cap Value

Company profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Booking Holdings Inc. Stock Rises Monday, Outperforms Market

4:41 pm ET March 20, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Booking Holdings Inc. (BKNG) advanced 2.17% to $2,493.73 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.89% to 3,951.57 and the Dow Jones Industrial Average rising 1.20% to 32,244.58. This was the stock's third consecutive day of gains. Booking Holdings Inc. closed $136.27 short of its 52-week high ($2,630.00), which the company achieved on March 7th.

Trading volume (322,397) remained 18,191 below its 50-day average volume of 340,588.

Data source: Dow Jones Market Data, FactSet. Data compiled March 20, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 20, 2023 16:41 ET (20:41 GMT)